NCT03236428: Phase 2: Phase II Study of the CD38 Antibody Daratumumab MGUS / Smoldering Myeloma SMM
Updated: May 23, 2022
NCT03236428: Phase 2: Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma
Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma
This research study is studying a drug as a possible treatment for Monoclonal Gammopathy of Unknown Significance (MGUS) or Smoldering Multiple Myeloma (SMM).
The drug involved in this study is:
-Daratumumab
Sponsor
Dana-Farber Cancer Institute
Collaborators
Janssen Pharmaceuticals
Multiple Myeloma Research Consortium
Blood Cancer Research Partnership
The Leukemia and Lymphoma Society
Information provided by (Responsible Party)
Irene Ghobrial, MD, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier: NCT03236428
Official Title: A Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma
First Posted: August 1, 2017
Click here to see details on ClinicalTrials.gov
Drug: Daratumumab
Locations
United States, California
United States, Colorado
United States, Massachusetts
United States, Michigan